电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Recombinant ADAR 抗体

This anti-ADAR antibody is a 兔 单克隆 antibody detecting ADAR in IHC 和 ELISA. Suitable for 人.
产品编号 ABIN7127324
发货至: 中国

Quick Overview for Recombinant ADAR 抗体 (ABIN7127324)

抗原

See all ADAR 抗体
ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

抗体类型

Recombinant Antibody

适用

  • 85
  • 29
  • 24
  • 2
  • 1
  • 1
  • 1
  • 1

宿主

  • 81
  • 5
  • 1

克隆类型

  • 74
  • 13
单克隆

标记

  • 37
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
This ADAR antibody is un-conjugated

应用范围

  • 58
  • 27
  • 27
  • 21
  • 20
  • 10
  • 10
  • 9
  • 8
  • 6
  • 3
  • 3
  • 1
Immunohistochemistry (IHC), ELISA

克隆位点

7H12
  • 交叉反应

    纯化方法

    Affinity-chromatography

    免疫原

    A synthesized peptide derived from human ADAR1

    亚型

    IgG
  • 应用备注

    Recommended dilution: IHC:1:50-1:200,

    限制

    仅限研究用
  • 状态

    Liquid

    缓冲液

    Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

    储存液

    Sodium azide

    注意事项

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    储存条件

    -20 °C,-80 °C

    储存方法

    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 抗原

    ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

    别名

    ADAR

    背景

    Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.

    Aliases: Double-stranded RNA-specific adenosine deaminase (DRADA) (EC 3.5.4.37) (136 kDa double-stranded RNA-binding protein) (p136) (Interferon-inducible protein 4) (IFI-4) (K88DSRBP), ADAR, ADAR1 DSRAD G1P1 IFI4

    UniProt

    P55265

    途径

    Protein targeting to Nucleus
You are here:
Chat with us!